Difference between revisions of "Tamoxifen"
Jump to navigation
Jump to search
| Line 5: | Line 5: | ||
==See also== | ==See also== | ||
*[[Clinical]]. | *[[Clinical]]. | ||
*[[Endometrium with changes due to selective progesterone receptor modulators]]. | |||
==References== | ==References== | ||
Latest revision as of 18:26, 30 August 2023
Tamoxifen is a drug that an anti-estrogen effect. It is used to treat breast cancer.
The classic teaching is that it increases the risk of endometrial cancer; however, the risk is quite small or possibly negligent.[1][2] Use is also associated with endometrial polyps.
See also
References
- ↑ Brown, K. (Sep 2009). "Is tamoxifen a genotoxic carcinogen in women?". Mutagenesis 24 (5): 391-404. doi:10.1093/mutage/gep022. PMID 19505894.
- ↑ Ashraf, M.; Biswas, J.; Majumdar, S.; Nayak, S.; Alam, N.; Mukherjee, KK.; Gupta, S.. "Tamoxifen use in Indian women--adverse effects revisited.". Asian Pac J Cancer Prev 10 (4): 609-12. PMID 19827879.